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Abstract
Background: Results of previous studies on the association between maternal haemoglobin concentration during
pregnancy and stillbirth risk are inconclusive. It is not clear if haemoglobin concentration before pregnancy has a
role. Using prospectively collected information from pre-pregnancy and antenatal visits, we investigated associations of
maternal haemoglobin concentrations before and during pregnancy and haemoglobin dilution with stillbirth risk.
Methods: In a population-based case–control study from rural Golestan, a province in northern Iran, we identified 495
stillbirths (cases) and randomly selected 2,888 control live births among antenatal health-care visits between 2007 and
2009. Using logistic regression, we estimated associations of maternal haemoglobin concentrations, haemoglobin
dilution at different stages of pregnancy, with stillbirth risk.
Results: Compared with normal maternal haemoglobin concentration (110–120 g/l) at the end of the second trimester,
high maternal haemoglobin concentration (≥140 g/l) was associated with a more than two-fold increased stillbirth risk
(OR = 2.31, 95 % CI [1.30–4.10]), while low maternal haemoglobin concentration (<110 g/l) was associated with a 37 %
reduction in stillbirth risk. Haemoglobin concentration before pregnancy was not associated with stillbirth risk. Decreased
haemoglobin concentration, as measured during pregnancy (OR = 0.61, 95 % CI [0.46, 0.80]), or only during the second
trimester (OR = 0.75, 95 % CI [0.62, 0.90]), were associated with reduced stillbirth risk. The associations were essentially
similar for preterm and term stillbirths.
Conclusions: Haemoglobin concentration before pregnancy is not associated with stillbirth risk. High haemoglobin level
and absence of haemoglobin dilution during pregnancy could be considered as indicators of a high-risk pregnancy.
Keywords: Stillbirth, Maternal anaemia, Haemoglobin concentration, Haemoglobin dilution, Adverse pregnancy outcome
Background
Results of previous studies on associations between ma-
ternal haemoglobin concentration and risks of preterm
birth, low birth weight, small for gestational age, and
stillbirth are inconclusive [1, 2]. We and others have
previously reported that both low and high haemoglobin
concentration during pregnancy may increase stillbirth
risk [2–4]. Yet, other studies have found that increased
stillbirth risk is restricted to women with either low [5]
or high [6] haemoglobin values.
During pregnancy, there is significant change in mater-
nal haemostatic profile [7], including haemoglobin dilu-
tion due to the expanding serum component of the
blood [8]. Disruption in this process, possibly due to
pathology in early pregnancy [9], seems to be associated
with adverse pregnancy outcomes [2]. However, it is not
clear if haemoglobin concentration before pregnancy
modifies this association.
In the Golestan province in northern Iran, the primary
health care organization provides modern antenatal and
obstetric care to virtually all pregnant women. In the
rural part of the province, most pregnancies are planned
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and most women have, following the recommendations
of the Alma Ata conference, a pre-pregnancy visit
followed by several antenatal visits [10]. Information on
maternal haemoglobin concentrations measured before
pregnancy and repeatedly during pregnancy is routinely
recorded.
In this population-based case–control study of still-
birth from the rural area of the Golestan province in
northern Iran, we studied associations of haemoglobin
concentrations before and during pregnancy with still-
birth risk, and also studied associations of maternal
haemoglobin dilution (average weekly change in haemo-
globin concentration) during the first and second
trimester of pregnancy with stillbirth risk.
Methods
Study setting
The study was performed in rural areas of the Golestan
province, in northeast Iran. Golestan province has a
population of approximately 1,700,000 inhabitants (50 %
living in rural areas), and has approximately 17,000
births annually. The public health care system in Iran
specifies that each rural health house is responsible for
providing care and recording information before and
during pregnancy and after delivery. Blood profile and
other laboratory data are routinely assessed at the pre-
pregnancy visit and twice during pregnancy. Such infor-
mation is prospectively recorded in the family health
files held by approximately 600 rural health houses.
Study design
The study design has been described in full elsewhere
[11]. All identified singleton stillbirths in the rural areas
of Golestan Province between 2007 and 2009 were
selected as cases. Stillbirth was defined as delivery of a
baby without any vital signs at 28 weeks of gestation or
later. We identified 501 singleton stillbirths, and after
excluding stillbirths without any maternal blood haemo-
globin concentration records during pregnancy, 495 still-
births were selected as cases. Controls were selected
using a stratified random sampling method. As growth
rate vary between regions of Golestan province, we de-
fined each region as a stratum and calculated the sample
size for each stratum. The proportion of registered preg-
nancies selected was based on the population growth
rate of the region. Each pregnancy had the same prob-
ability to be selected. We selected controls using random
digits generated by computer. We aimed to have at least
five controls per case after excluding births before 28
gestational weeks, multiple births, and stillbirths. The
control group comprised 2,888 live singleton births with
a gestational age of at least 28 completed weeks.
Information on maternal and pregnancy characteristics
were collected from medical records by midwifes
working at the health centres. Data were abstracted
from pre-pregnancy, pregnancy and delivery records,
and information was entered using Access software
by ten specially trained medical students. Each record,
including information on the mother, children and
spouse, received a unique code at the time of data
collection and these codes were used during data
entry to identify individuals and make it possible to
analyse the data anonymously. The measurement of
socioeconomic circumstances was based on husband’s
profession (unskilled manual worker, skilled manual
worker, self-employed, farmer, other occupations, and
unemployed). Self-reported information on current or
previous smoking and opium use was also collected.
As a quality control, we collected and computerized 10 %
of the data a second time. The variables that had more
than 5 % mismatches were recollected and the data re-
entered for all study subjects. If the data for a health
centre had more than 5 % mismatches, all data were
recollected and re-entered for that centre.
Based on the “Iranian National Antenatal Care” proto-
cols in the primary health care system, laboratory testing
(included complete blood count test, blood biochemistry
profile, and urine analysis) was performed twice during
pregnancy: at 6 to 10 and at 26 to 30 gestational weeks.
The mean gestational ages for the first and second
haemoglobin concentration measurements were 9 weeks
and 28 weeks for both cases and controls. Haemoglobin
dilution during the second trimester of pregnancy was
calculated as the difference between blood haemoglobin
concentration at the first and last measurement during
pregnancy, divided by the time period (completed
weeks) between the two measurements (mean change in
haemoglobin concentration per gestational week). Ob-
servations with a time interval of less than three weeks
between two haemoglobin measurements were excluded
from the analysis of haemoglobin dilution (n = 3).
Among all cases (n = 495) and controls (n = 2,888), 158
cases and 1,225 controls also had a recorded blood
haemoglobin concentration during the year before preg-
nancy. For this group we also estimated haemoglobin
dilution during pregnancy, defined as the difference be-
tween the pre-pregnancy and the last pregnancy meas-
urement of blood haemoglobin concentration, divided
by gestational age (in completed weeks) at the last
measurement.
Gestational age was based on the time interval
between date of delivery and date of the first day of the
last menstrual period. Preterm delivery was defined as a
delivery before 37 completed weeks. As a proxy measure
for foetal growth restriction, we used small for gesta-
tional age (SGA), which was defined as a birth weight
below the 10th percentile (in the control group) for
gestational age (week) and sex. Because of the limited
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number of preterm births in the control group, we could
not estimate appropriate cut off limits for SGA in pre-
term deliveries. Maternal blood pressure was measured
before pregnancy, at least 8 times during pregnancy and
after delivery. Hypertension was defined as a measured
systolic blood pressure ≥140 and/or diastolic blood
pressure ≥90 during each trimester of pregnancy.
The study was approved by the Research Ethics
Committee of Golestan University of Medical Sciences
and the Karolinska Institutet regional ethics committee.
The ethical committees did not require written informed
consent for participation in the study.
Statistical analysis
We used univariable and multivariate logistic regression
models to estimate odds ratios (ORs) and 95 % confi-
dence intervals (CIs) for the associations of maternal
haemoglobin concentrations, haemoglobin dilution, with
stillbirth risk. As the outcome is rare in both exposed
and unexposed mothers, the odds ratio approximates
the risk ratio and the results are described in terms of
risk ratio throughout the paper. The multivariate models
were adjusted for maternal age, pre-pregnancy body
mass index (BMI), height, gestational age at the first
haemoglobin measurement, parity (0, 1–2, >2), smoking
status, region of residence, and husband’s profession.
We also investigated possible nonlinear effects of age
and BMI by introducing age squared and BMI squared
into the adjusted model. However, these variables had
not notable effects and were therefore not included in
the final models.
Pregnancy-induced hypertensive diseases are related to
both stillbirth risk [12] and haemoglobin concentration
during pregnancy [13]. Information on preeclampsia or
eclampsia was not available, but we performed a sensi-
tivity analysis after excluding all subjects with a record
of hypertension during pregnancy.
We estimated odds ratios for stillbirth associated with
maternal haemoglobin concentrations before pregnancy,
in the first trimester, and in the second trimester of
pregnancy. We estimated the risks using both maternal
haemoglobin concentration as a continuous variable
(gram per litter [g/l]), and as a four-category measure
(<110, 110–120, 120–139, and ≥140 g/l). We also esti-
mated odds ratios for stillbirth associated with haemo-
globin dilution in each gestational week: a) during
pregnancy (>0.78, 0.78–0.01, and ≤ 0.00 g/l), and b) dur-
ing the second trimester of pregnancy (>0.78, 0.78–0.01,
and ≤ 0.00 g/l). The haemoglobin categories were based
on tertiles of the distribution in the control group.
A multiple imputation method was used to provide
data where there were missing values for maternal age
(32 among controls) and husband’s profession (16 among
cases and 79 among controls) [14]. The MI procedure
(SAS software) with five imputations was used. We
also performed a sensitivity analysis by restricting the
analysis to observations without any missing data.
SAS software version 9.3 was used for analysing
the data.
Results
Maternal characteristics of cases and controls are pre-
sented in the Table 1. Associations of the maternal
haemoglobin concentrations with risk of stillbirth are
presented in Table 2. Maternal haemoglobin concentra-
tion measured before pregnancy was not associated with
stillbirth risk. Compared with normal maternal haemo-
globin values (110–120 g/l) at the end of the first trimes-
ter, high haemoglobin values (≥140 g/l) were associated
with a 36 % increased risk of stillbirth. Compared with
normal haemoglobin values at the second trimester of
pregnancy, high maternal haemoglobin values were asso-
ciated with a more than two-fold increased risk of still-
birth, and low haemoglobin concentration (≤110 g/l)
was associated with a reduced stillbirth risk. We also es-
timated associations between the maternal haemoglobin
concentrations and risk of stillbirth stratified by gesta-
tional age (preterm and term stillbirth), which showed
no notable differences in the results (Additional file 1).
The associations between level of haemoglobin dilu-
tion and stillbirth risk are shown in Table 3. Compared
with mothers who did not have any change in haemoglo-
bin concentration during the second trimester, those
with decreased haemoglobin concentration had a reduced
stillbirth risk. For the subsample where information on
pre-pregnancy haemoglobin concentration was available,
we also estimated haemoglobin dilution during pregnancy
(from before pregnancy to last measurement during
pregnancy). Compared with those who did not have any
change in haemoglobin concentration during pregnancy,
those with decreased haemoglobin concentration had a
reduced stillbirth risk. There was a dose–response associ-
ation between haemoglobin dilution as an exposure
and stillbirth risk, both in the analysis of the second
trimester and in the analysis of pregnancy.
We also performed a sensitivity analysis after ex-
cluding all pregnancies with a record of hypertension
(systolic blood pressure ≥140 and/or diastolic blood
pressure ≥90) during pregnancy. After excluding 36
cases and 102 controls with hypertensive disorders, the
results were virtually unchanged (data not shown).
Table 4 shows associations between average weekly
change in haemoglobin concentration and risks of pre-
term and term stillbirth. There was no substantial differ-
ence between risks for term and preterm stillbirth using
the categorical variable: higher levels of haemoglobin
dilution were associated with lower risk of preterm still-
birth and there was a dose response association (p for
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trend <0.01). For term stillbirth, we observed a statisti-
cally significant 25 % risk reduction for an average of
one g/l weekly change in haemoglobin during the second
trimester. For preterm stillbirth, the corresponding point
estimate was identical, but not statistically significant
(Table 4).
Table 5 shows associations between average weekly
change in haemoglobin concentration and stillbirth
stratified by SGA stillbirths and non-SGA stillbirths in
term deliveries. Using the measure of change in haemo-
globin concentration as a continuous variable, we observed
a 40 % risk reduction of SGA stillbirth for each g/l weekly
change in haemoglobin during the second trimester.
Haemoglobin dilution was not associated with a reduced
risk of non-SGA term stillbirth. Restricting analyses to
observations without any missing data did not change the
results notably.
Discussion
This population-based case–control study showed that
haemoglobin concentration before pregnancy was not
associated with stillbirth risk. High and low haemoglobin
Table 1 Maternal characteristics for 495 stillbirths and 2,888 live
singleton births in Golestan, Iran
Cases Controls
n (%) n (%)
Mother’s age, year
≤ 19 72 (14.5) 363(12.6)
20-24 127 (25.7) 865 (30.0)
25–29 138 (27.9) 760 (26.3)
30–34 92 (18.6) 589 (20.4)
≥ 35 66 (13.3) 279 (9.7)
Missing 0 (0) 32 (1.1)
Body mass index
< 18.5 39 (7.9) 200 (6.9)
18.5 to <25 180 (36.4) 1,426 (49.4)
25 to <30 117 (23.6) 655 (22.7)
30 to <35 56 (11.3) 230 (8.0)
≥ 35 26 (5.3) 60 (2.1)
Missing 77 (15.6) 317 (11.0)
Mother’s height, cm
< 150 48 (9.7) 192 (6.6)
150–154 116 (23.4) 590 (20.4)
155–159 152 (30.7) 921 (31.9)
160–164 55 (11.1) 479 (16.6)
≥ 165 47 (9.5) 389 (13.5)
Missing 77 (15.6) 317 (11.0)
Parity
0 256 (51.7) 1,140 (39.5)
1–2 192 (38.8) 1,338 (46.3)
≥ 3 32 (6.5) 189 (6.5)
Missing 15 (3.0) 221 (7.7)
Pregnancy induced hypertension
459 (92.7) 2,786 (96.5)
36 (7.3) 102 (3.5)
Smoking
No 488 (98.6) 2,803 (97.1)
Yes 7 (1.4) 85 (2.9)
Husband’s profession
Unemployed 16 (3.2) 76 (2.6)
Non skill worker 206 (41.6) 1,318 (45.6)
Skill worker 55 (11.1) 275 (9.5)
Self-employed 78 (15.8) 327 (11.3)
Farmer 79 (16.0) 547 (18.9)
Other 44 (8.9) 266 (9.2)
Missing 17 (3.4) 79 (2.7)
Table 1 Maternal characteristics for 495 stillbirths and 2,888 live
singleton births in Golestan, Iran (Continued)
Haemoglobin concentration before pregnancy (g/l)
Mean (SD) 126.3 (10.4) 125.7 (11.4)
Median (Range) 130.0 (100–150) 120.0 (80–160)
Haemoglobin concentration at first trimester (g/l)
Mean (SD) 124.5 (12.3) 122.7 (11.7)
Median (Range) 120.0 (80 to 170) 120.0 (70 to 160)
Haemoglobin concentration at end of second trimester (g/l)
Mean (SD) 117.1 (11.6) 113.5 (11.3)
Median (Range) 120.0 (80–150) 110.0 (70–170)
Region
Aghghala 51 (10.3) 377 (13.1)
Aliabad 28 (5.7) 183 (6.3)
Azadshahr 32 (6.5) 142 (4.9)
Bandargaz 7 (1.4) 114 (3.9)
Galikesh 23 (4.6) 115 (4.0)
Gomishan 37 (7.5) 104 (3.6)
Gonbad 130 (26.3) 524 (18.1)
Gorgan 15 (3.0) 284 (9.8)
Kalaleh 65 (13.1) 361 (12.5)
Kordkoy 14 (2.8) 84 (2.9)
Maraveh 37 (7.5) 168 (5.8)
Minoodasht 23 (4.6) 235 (8.1)
Ramian 17 (3.4) 102 (3.5)
Torkaman 16 (3.2) 95 (3.3)
Maghsoudlou et al. BMC Pregnancy and Childbirth  (2016) 16:135 Page 4 of 8
concentrations at the end of the second trimester were
associated with an increased and a reduced stillbirth
risk, respectively. Decreased haemoglobin concentration,
during the entire pregnancy or during the second
trimester, was also associated with reduced stillbirth risk.
Our findings are consistent with other studies,
reporting positive associations between increasing mater-
nal haemoglobin levels in early [2, 15] or late pregnancy
[16] and risk of stillbirth or other adverse outcomes
[13, 17–19]. During pregnancy, plasma renin activity
increases [9, 20] and the atrial natriuretic peptide
levels decrease to meet demands of new vascular beds
[21, 22]. High maternal erythropoietin secretion dur-
ing pregnancy causes an increase in red blood cell
mass. However, this increase is less than the change
in the plasma volume, which causes a 10 to 20 gram
decrease in haemoglobin concentration per litre plasma
at the end of the second trimester in normal pregnancy
Table 2 Haemoglobin concentration and the risk of stillbirth
Cases Controls Odds Ratio (95 % Confidence Interval)
n (%) n (%) Crude Adjusteda
Haemoglobin concentration before pregnancy (g/l)
< 110 4 (2.5) 31 (2.5) 1.04 (0.36–3.04) 1.23 (0.39–3.84)
110–120 72 (45.6) 582 (47.5) Reference Reference
121–139 49 (31.0) 360 (29.4) 1.10 (0.75–1.61) 0.97 (0.64–1.47)
≥ 140 33 (20.9) 252 (21.0) 1.06 (0.68–1.64) 0.83 (0.52–1.34)
Continuous 158 (100) 1,225 (100) 1.00 (0.99–1.02) 1.00 (0.98–1.01)
Haemoglobin concentration at first trimester (g/l) (gestational age weeks between 6 to 10)
< 110 26 (5.3) 181 (6.5) 0.91 (0.59–1.40) 0.87 (0.55–1.37)
110–120 223 (46.1) 1,411 (50.5) Reference Reference
121–139 152 (31.4) 834 (30.0) 1.45 (0.92–1.44) 1.18 (0.94–1.49)
≥ 140 83 (17.1) 366 (13.1) 1.43 (1.09–1.89) 1.36 (1.01–1.81)
Continuous 484 (100) 2,792 (100) 1.01 (1.00–1.02) 1.01 (1.00–1.02)
Haemoglobin concentration at end of second trimester(g/l) (gestational age weeks between 26 to 30)
< 110 37 (14.0) 523 (21.2) 0.64 (0.44–0.92) 0.63 (0.43–0.92)
110–120 180 (65.2) 1,618 (65.6) Reference Reference
121–139 40 (14.4) 268 (10.9) 1.34 (0.93–1.93) 1.19 (0.81–1.74)
≥ 140 18 (6.4) 59 (2.4) 2.74 (1.58–4.75) 2.31 (1.30–4.10)
Continuous 275 (100) 2,468 (100) 1.03 (1.02–1.04) 1.03 (1.01–1.04)
aAdjusted for maternal age, maternal height, maternal BMI, parity, smoking status, husband’s profession, region and gestational age at haemoglobin measurement
Table 3 Haemoglobin dilution and the risk of stillbirth
Cases Controls Odds Ratio (95 % Confidence Interval)
n (%) n (%) Crude Adjusteda
Haemoglobin dilution during second trimester of pregnancy (g/l)
> 0.78 70 (26.7) 765 (33.8) 0.57 (0.42–0.78) 0.54 (0.39–0.74)
0.78–0.01 73 (27.9) 750 (33.2) 0.61 (0.45–0.83) 0.62 (0.45–0.85)
0.00 ≤ 119 (45.4) 745 (33.0) Reference Reference
P for trend <0.0001
Continuous 262 (100) 2,260 (100) 0.76 (0.63–0.92) 0.75 (0.62–0.90)
Haemoglobin dilution during pregnancy (g/l)
> 0.69 31 (20.0) 392 (33.1) 0.33 (0.21–0.51) 0.33 (0.21–0.52)
0.69–0.01 38 (24.5) 430 (36.3) 0.37 (0.25–0.56) 0.42 (0.27–0.66)
0.00 ≤ 86 (55.5) 361 (30.5) Reference Reference
P for trend <0.0001
Continuous 155 (100) 1,183 (100) 0.58 (0.45–0.74) 0.61 (0.46–0.80)
aAdjusted for maternal age, maternal height, maternal BMI, parity, gestational age at first haemoglobin measurement, smoking status, husband’s profession, and region
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[7]. High blood haemoglobin levels may be a conse-
quence of disturbance in the physiology of expanding
the serum component of the maternal blood during
pregnancy [23, 24].
We also observed that decreased haemoglobin concen-
tration during pregnancy was associated with lower risk
of stillbirth, regardless of initial haemoglobin level or
time of the change in haemoglobin concentration. This
protective effect was also observed in previous studies
on stillbirth [2], preeclampsia [25], and low birth weight
[25, 26]. However, previous studies did not have pre-
pregnancy data to investigate the possible role of haemo-
globin concentration before pregnancy. The association
was essentially similar between preterm and term still-
births, and if anything, more marked among SGA still-
births in term pregnancies. These findings, which are
consistent with the results of a Swedish study [2], may
indicate that the risk of stillbirth related to high haemo-
globin concentration during pregnancy might be asso-
ciated with impaired foetal growth. We did not have
enough data to investigate risks stillbirth risks associated
with impaired foetal growth in preterm pregnancies or
stillbirths with malformations.
Preeclampsia is associated with both stillbirth risk [12]
and haemoglobin concentration during pregnancy [13]
and this disorder could be an intermediate factor. As in-
formation on preeclampsia or eclampsia was not avail-
able, we reanalysed the data after excluding all subjects
with a record of hypertension during pregnancy. We
observed no notable change in the results. This is in
contrast with the results of a Swedish study [2] in which
the stillbirth-related risks associated with a high haemo-
globin concentration increased when women with pre-
eclampsia or eclampsia were excluded.
To the best of our knowledge, there are no published
data on the association between haemoglobin concentra-
tion prior to pregnancy and risk of stillbirth. The lack of
association between haemoglobin concentration before
pregnancy and stillbirth in this study could be because
women with a low haemoglobin concentration receive
pharmacological treatment before pregnancy. Based on
routines in the primary health care system in Iran, more
than 90 % of pregnant women receive iron and other
micro-supplements after the 16th week of pregnancy.
Moreover, women of reproductive age undergo screen-
ing to identify and treat iron deficiency anaemia,
particularly before pregnancy [10] which can increase
haemoglobin concentration [27]. This practise eliminates
to a large extent the possible effects of iron deficiency in
our study. Iron deficiency can be a major contributory
Table 4 Haemoglobin dilution and risks of preterm and term stillbirth
Preterm stillbirth Term stillbirth
Cases (n = 81) Controls (n = 2,260) Odds ratioa (95 % CI)b Cases (n = 181) Controls (n = 2,105) Odds ratioa
(95 % CI)bn (%) n (%) n (%) n (%) n (%)
Haemoglobin dilution during second trimester of pregnancy (g/l)
> 0.78 22 (27.6) 765 (33.8) 0.49 (0.28–0.84) 48 (26.5) 716 (34.0) 0.55 (0.38–0.81)
0.78–0.01 20 (24.7) 750 (33.2) 0.50 (0.28–0.87) 53 (29.3) 701 (33.3) 0.67 (0.46–0.97)
0.00 ≤ 39 (48.1) 745 (33.0) Reference 80 (44.2) 688 (32.7) Reference
P for trend <0.01 <0.01
Continuous 81 (100) 2,260 (100) 0.75 (0.54–1.06) 181 (100) 2,105 (100) 0.75 (0.61–0.93)
aAdjusted for: maternal age, maternal height, maternal BMI, parity, gestational age at first haemoglobin measurement, history of smoking, husband’s profession,
and region
bOR denotes Odds ratios and CI denotes confidence intervals
Table 5 Haemoglobin dilution and risks of SGA and Non-SGA in term stillbirth
SGA stillbirth Non-SGA stillbirth
Cases (n = 55) Controls (n = 215) Odds ratioa
(95 % CI)b
Cases (n = 75) Controls (n = 1,858) Odds ratioa
(95 % CI)bn (%) n (%) n (%) n (%)
Haemoglobin dilution during second trimester of pregnancy (g/l)
> 0.78 12 (26.4) 66 (34.0) 0.48 (0.19–1.22) 20 (26.7) 639 (34.4) 0.62 (0.34–1.11)
0.78–0.01 18 (25.5) 67 (33.3) 1.01 (0.43–2.39) 26 (34.7) 621 (33.4) 0.87 (0.50–1.52)
0.00 ≤ 25 (48.1) 82 (32.6) Reference 29 (38.7) 598 (32.2) Reference
Continuous 55 (100) 215 (100) 0.59 (0.36–0.97) 75 (100) 1,858 (100) 0.95 (0.68–1.33)
aAdjusted for: maternal age, maternal height, maternal BMI, parity, gestational age at first haemoglobin measurement, history of smoking, husband’s profession,
and region
bOR denotes Odds ratios and CI denotes confidence intervals
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factor to both haemoglobin dilution and serious mater-
nal anaemia, [7] which might increase risk of adverse
pregnancy outcomes such as preterm birth and low birth
weight [1]. A recent meta-analysis showed that prenatal
iron use is associated with a significant increase in birth
weight and reduction in risk of low birth weight [28].
However, prenatal daily iron supplement intake might
also be associated with risk of higher haemoglobin
concentration during pregnancy [29]. Therefore, it is
questionable whether women with normal blood values
benefit from taking iron supplements [30].
Strengths of the study include the use of prospectively
collected information from antenatal visits. We included
all cases and randomly selected controls with informa-
tion on maternal blood profile, and extracted prospect-
ively recorded information from family health records,
which minimizes risks of selection and recall bias. This
study was conducted in rural areas of Golestan province,
where most pregnancies are planned, and some 97 % of
pregnant women are in contact with the primary health
care system.
This study has also some potential limitations. Mater-
nal blood profile was tested in different laboratories
which may had different methods and accuracy. As re-
corded haemoglobin concentrations were rounded to the
nearest half unit, we did not have information on exact
values. The number of women with a very low haemo-
globin concentration was small and we could not esti-
mate the risk of stillbirth among this group. As stillbirth
was defined as delivery of a baby without any vital signs
at 28 weeks of gestation or later, we did not have any
information on very preterm stillbirth (less 28 weeks
gestational age). This helps to explain the low propor-
tion of preterm stillbirths in our study. Smoking is
culturally not accepted in rural area of Iran, and some
women may have not have reported history of smoking
accurately. As we used prospectively collected informa-
tion before and during pregnancy, possible misclassifica-
tion of smoking status would be non-differential, and if
anything, shift the association toward the null. Opium
use exists among women of childbearing age in Iran
[31]. In Golestan province most of the married women
(more than 90 %) are housewives and we did not have
any information about educational level of the mothers.
Another limitation is that the husband’s profession,
which is used as measure of socioeconomic conditions
for families, may not be sufficiently discriminatory. We
restricted our study to pregnancies in rural areas of the
Golestan province and there may be concern regarding
generalizability of the results. Exclusion of those with
missing haemoglobin values might cause selection bias.
Finally, we did not have any data to determine the cause
of the stillbirth, specifically genetic testing, autopsy, or
placental pathology or congenital defects; therefore we
could not investigate difference in the association
between haemoglobin concentration and stillbirth by
malformation.
Conclusions
In conclusion, this study showed that haemoglobin
concentration before pregnancy was not associated with
stillbirth risk. This study also provides evidence that
elevated maternal haemoglobin level during pregnancy is
a risk factor for stillbirth, and low haemoglobin level is
inversely associated with stillbirth. High haemoglobin
level and absence of haemoglobin dilution during preg-
nancy could be considered as indicators of a high-risk
pregnancy, regardless of haemoglobin concentration
before pregnancy.
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